Ask a haematologist in Patna what they wish general practitioners understood better, and haemoglobinopathy screening comes up quickly. Not because the tests are complicated. Because the wrong test gets ordered, and the result gets trusted.
Bihar and the eastern states carry a real burden of beta-thalassaemia trait, HbE, and sickle cell in particular districts. Two carriers who never knew they were carriers can produce a child with transfusion-dependent disease, and the only thing standing between that and a normal pregnancy is a screening test done properly at the right time.
Capillary electrophoresis is what does it properly.
## What it actually does
Haemoglobin variants differ in charge. Put them in a narrow capillary with a buffer and a voltage across it, and they migrate at different speeds and separate into distinct peaks. A detector reads the peaks and quantifies each fraction.
The output is not a number. It is a trace, with HbA, HbA2, HbF and any variants sitting in their own positions, each with a percentage against it.
That trace is the point. A raised HbA2 above roughly 3.5 per cent is the marker of beta-thalassaemia trait, and quantifying it accurately is the whole test. Systems like the Sebia Minicap resolve HbA2 well enough to make that call reliably, which older gel methods struggled with because HbA2 is a small fraction and gel scanning is imprecise at low percentages.
## Why HPLC and electrophoresis are not interchangeable here
Both are good methods. They separate on different principles — HPLC by column chemistry, capillary electrophoresis by charge — and they resolve different things well.
The one that matters in this region is HbE. On HPLC, HbE elutes very close to HbA2, and depending on the system the two can overlap enough that HbA2 is over-reported. Since HbA2 is exactly the number you are using to call thalassaemia trait, that overlap can turn an HbE trait into an apparent beta-thalassaemia trait, or mask a coinherited condition.
Capillary electrophoresis separates them cleanly. In a population where HbE is present, that is not a technical nicety.
None of which means HPLC is the wrong instrument. It means that if your screening population includes HbE, you should know how your method handles it, and have a confirmatory route.
## The pre-analytical trap
Iron deficiency lowers HbA2.
That sentence causes more missed thalassaemia trait than any instrument limitation. A woman who is iron deficient — which, in this population, a great many women of reproductive age are — can have a beta-thalassaemia trait masked by a falsely normal HbA2. She gets told she is a non-carrier. Her husband gets tested, comes back a carrier, and everyone relaxes.
Screen the iron status alongside, or repeat the electrophoresis after iron replacement. A ferritin costs very little compared with the consequence of getting this wrong.
The other trap is recent transfusion. Circulating donor cells give you the donor's haemoglobin pattern, not the patient's. Wait three months.
## Where it fits clinically
Antenatal screening is the highest-value application, and it works only if it happens early enough for the couple to have options. Screening in the third trimester is a formality.
Beyond that: any unexplained microcytic anaemia that has not responded to iron, family screening once an index case is found, and pre-marital screening where communities have taken it up.
A useful discipline for the report: if the microcytosis is disproportionate to the degree of anaemia, and the RDW is relatively normal, think trait rather than deficiency and say so in a comment. Clinicians act on comments far more than on numbers they were not expecting.
We supply and support capillary electrophoresis systems across Bihar and Jharkhand. If you are considering starting a screening service, the equipment is the straightforward part — it is worth talking through the confirmatory pathway and the iron-status question before you commit to a method.